Directory

BOADA ROVIRA, Mercè

Department of Medicine

BOADA ROVIRA, Mercè

CV

Teacher profile

Medicine, Faculty of Medicine and Health Sciences. Universitat Internacional de Catalunya

Education

Mercè Boada has a Degree in Medicine and Surgery from Universitat de Barcelona (1973). She specialized in Neurology at Hospital Vall d’Hebron de Barcelona (1974-1977). She received additional postgraduate training in Work Medicine, Health Institution Business Administration, and Geriatrics and Gerontology. She holds a PhD Degree in Medicine from Universitat Autònoma de Barcelona (1993).

Professional experience

Mercè has worked at Fundació ACE, Institut Català de Neurociències Aplicades, since October 1995. Previously she held diverse positions as the Head of the Dementia Unit in the Neurology Department of Hospital Universitari Vall d’Hebron (2007-2013), Head Medical Doctor of the Accident and Emergency Department (1988-1994), and specialist in the Neurology Department (1977-2013) at the same center. She is author of more than 220 papers in indexed scientific journals and has participated in numerous reseach, development, and innovation projects.

Publications

Articles

Projects and research

  • Identifying preclinical Alzheimer´s disease in the community using a panel of biomarkers among individuals with Subjective Memory Complaints (IPACBIS)01/03/2018
    IP: Boada, M.
    European Comission
  • Neural-derived plasma exosomes as biomarkers in the clinico-biological characterization of early onset mild cognitive impairment (BIOFACE)01/01/2018
    IP: Boada, M.
    Instituto de Salud Carlos III
  • A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease26/01/2017
    IP: Abbvie, I.
    AbbVie
  • A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Dementia (The DAYBREAK Study)01/01/2017
    IP: Eli Lilly, C.
    Eli Lilly and Company
  • MOPEAD. Models Of Patient Engagement for Alzheimer’s Disease01/10/2016
    IP: Boada, M.
    European Comission
  • A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease20/06/2016
    IP: Eisai, C.
    Eisai
  • PreDADQoL. Ethical and Legal Framework for Predictive Diagnosis of Alzheimer’s Disease: Quality of Life of Individuals at Risk and their Close Others01/06/2016
    IP: Hospital of Cologne, U.
    European Commission
  • A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). (CREAD)22/03/2016
    IP: La Roche, H.
    Hoffmann-La Roche
  • Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease (DIALRET)01/09/2014
    IP: Hernandez, C.
    Institut de Recerca Hospital Universitari Vall d'Hebron
  • Evaluación de la eficacia del empleo de infusiones intravenosas de trifosfato de adenosina (ATP) en mejora de la calidad de vida de pacientes afectados de Enfermedad de Alzheimer moderada y grave: Prueba de concepto aleatorizada, estratificada por test farmacogenético, doble-ciego y controlada mediante placebo01/01/2011
    IP: Boada, M.
    Ministerio de Sanidad, Política Social e lgualdad